Drug Topics November 7, 2022
Tackling Medicare Part D drug costs takes more than just capping costs.
The current cost sharing structure of Medicare Part D leaves many cancer patients feeling an economic pinch. Most beneficiaries have no limit on out-of-pocket costs and those costs are often calculated as a percentage of the list price instead of fixed copays. A recent editorial published in JAMA Oncology1 addressed the concerns.
With new cancer treatments having out-of-pocket costs of more than $10,000 per year, per drug, costs can quickly add up. A subsidy program exists for low-income Medicare patients, but only around 25% of beneficiaries qualified for this assistance in 2021. By comparison, other programs such as the Affordable Care Act and Tricare have much lower caps...
Today's Sponsors
Today's Sponsor